<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="43671">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02037425</url>
  </required_header>
  <id_info>
    <org_study_id>13-002AL</org_study_id>
    <nct_id>NCT02037425</nct_id>
  </id_info>
  <brief_title>Duration of Benefit for OnabotulinumtoxinA in Treatment of Chronic Migraine</brief_title>
  <official_title>Exploratory Study of the Natural History, Clinical Outcomes, and Neuronal Endplate Changes in Subjects Reporting Short Duration vs. Long Duration of Benefit for OnabotulinumtoxinA in Treatment of Chronic Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cady, Roger, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cady, Roger, M.D.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To obtain a patient specific understanding of  response to treatment with onabotulinumtoxinA
      by collecting and correlating pre and post treatment  subject specific history, clinical
      outcomes, and histological changes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recognizing a commitment to evidence-based science as the pathway to optimize clinical
      outcomes for patients with chronic migraine (CM) we believe this investigator initiated
      study (IIS) will:

        1. Help clinicians recognize the importance of scheduling patients with CM at intervals
           not exceeding 12 weeks.

        2. Provide biopsy evidence supporting sensory mechanisms involved in the mechanism of
           action (MOA) of onabotulinumtoxinA (BTX).  This does not exclude potential valuable
           contributions of denervation of motor neurons, but may support a more balanced and
           understandable mechanism for BTX in treating CM.

        3. Provide clinicians important educational information for patients to better manage
           expectations of using BTX in managing CM and answering critical questions such as:

             1. How long does it take for BTX to begin providing a clinical benefit?

             2. What is the expected duration of this benefit?

                  -  Failure to understand unmet expectations either real or otherwise results in
                     defining BTX treatment as a failure by patients and/or clinicians.

        4. Provide validation for patients' reports of shorter duration of action of BTX so
           patients will not be misinterpreted as non-responders to BTX prematurely.

        5. Ascertain if subjects initially reporting short duration of BTX response continue to
           experience this similar pattern of effect with repeated injection cycles.

        6. Provide the first detailed longitudinal assessment of BTX response.

        7. Correlate the onset and duration of benefit for subjects receiving BTX.

        8. Observe factors predictive of duration of BTX response.

      This study proposes to accomplish these goals through an exploratory comparison of the
      clinical efficacy and natural history of BTX measured at weekly time intervals.  Subjects
      reporting short (&lt;10 weeks) duration of benefit and subjects reporting long (&gt;10 weeks)
      duration of clinical benefit will provide the primary comparison.  Histological examinations
      (in a subset of subjects) of neuronal changes associated with regeneration of terminal
      neuronal endplates will be used to support these clinical observations.  This study will
      follow subjects through 3 injection cycles or 36 weeks. Biopsies will be performed on
      consenting subjects prior to their first and second injection cycles.

      Group Assignment

      At Visit 3, subjects will be assigned to one of three groups (Groups A, B, C) based on their
      answers to the following questions:

        1. Since your last BTX treatment, do you think there has been improvement in your chronic
           migraine? If the answer to Q1 is yes, subject will answer Q2 and Q3.  If the answer is
           no, subject is assigned to Group C and no further answers are required:

        2. How many days did it take for you to first notice benefit from BTX injections?

        3. How long did you feel you received benefit from BTX (number of weeks)?

      Subjects will be assigned into 3 groups:

        1. Group A are subjects reporting 10 or less weeks of benefit from BTX;

        2. Group B are subjects reporting &gt;10 weeks of benefit from BTX;

        3. Group C are subjects reporting no or minimal (&lt; 30%) benefit from BTX.

      Consistency of subjects' perception of BTX benefit at 12 weeks will be compared to responses
      at 24 and 36 weeks, though Group assignment will remain as defined at 12 weeks.

      This exploratory study will be conducted at the Headache Care Center in Springfield, MO.
      Thirty-six subjects, 18 years and older with a history of chronic migraine will be enrolled.
       The study will consist of 5 visits for all subjects.

      At Visit 1 (day 1 of baseline) the following study procedures will be performed:

        -  Informed Consent obtained

        -  Migraine, medical and medication history obtained

        -  Physical and neurological exam performed

        -  Urine pregnancy test performed if applicable

        -  Vital signs collected

      At Visit 2 (day 29 +/- 3 days) the following study procedures will be performed:

        -  Update medical and medication history

        -  Urine pregnancy test performed if applicable

        -  Vital signs collected

        -  Review baseline diary

        -  Complete Migraine Disability Assessment Scale (MIDAS)

        -  Complete Social Readjustment Rating Scale (SRRS)

        -  Complete Beck Depression Inventory II (BDI-II)

        -  Complete State-Trait Anxiety Inventory (STAI)

        -  Complete Sleep Quality Questionnaire

        -  Punch biopsy for neuronal regrowth (subset of subjects)

        -  onabotulinumtoxinA injections

      At Visit 3 (day 113 +/- 3 days) the following study procedures will be performed:

        -  Update medical and medication history

        -  Urine pregnancy test performed if applicable

        -  Vital signs collected

        -  Complete Subject Global Impression of Change (SGIC)

        -  Complete Physician Global Impression of Change (PGIC)

        -  Complete Migraine Disability Assessment Scale (MIDAS)

        -  Complete Social Readjustment Rating Scale (SRRS)

        -  Complete Beck Depression Inventory II (BDI-II)

        -  Complete State-Trait Anxiety Inventory (STAI)

        -  Complete Sleep Quality Questionnaire

        -  Complete duration of response to onabotulinumtoxinA questions

        -  Punch biopsy for neuronal regrowth (subset of subjects)

        -  onabotulinumtoxinA injections

      At Visit 4 (day 197 +/- 3 days) the following study procedures will be performed:

        -  Update medical and medication history

        -  Urine pregnancy test performed if applicable

        -  Vital signs collected

        -  Complete Subject Global Impression of Change (SGIC)

        -  Complete Physician Global Impression of Change (PGIC)

        -  Complete Migraine Disability Assessment Scale (MIDAS)

        -  Complete Social Readjustment Rating Scale (SRRS)

        -  Complete Beck Depression Inventory II (BDI-II)

        -  Complete State-Trait Anxiety Inventory (STAI)

        -  Complete Sleep Quality Questionnaire

        -  Complete duration of response to onabotulinumtoxinA questions

        -  onabotulinumtoxinA injections

      At Visit 5 (day 281 +/- 3 days) the following study procedures will be performed:

        -  Update medical and medication history

        -  Urine pregnancy test performed if applicable

        -  Vital signs collected

        -  Complete Subject Global Impression of Change (SGIC)

        -  Complete Physician Global Impression of Change (PGIC)

        -  Complete Migraine Disability Assessment Scale (MIDAS)

        -  Complete Social Readjustment Rating Scale (SRRS)

        -  Complete Beck Depression Inventory II (BDI-II)

        -  Complete State-Trait Anxiety Inventory (STAI)

        -  Complete Sleep Quality Questionnaire

        -  Complete duration of response to onabotulinumtoxinA questions
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Subject Global Impression of Change</measure>
    <time_frame>From day 1 (first day of baseline) to day 281 (84th day of injection cycle 3) plus or minus 12 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Changes in the Subject's Global Impression of Change (SGIC) measured at weeks 12, 24, and 36 for Groups A, B, and C.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of onabotulinumtoxinA Over 3 Injection Cycles in Groups A, B, and C</measure>
    <time_frame>From day 29 (first day of injection cycle 1) to day 281 (84th day of injection cycle 3) plus or minus 12 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Compare the duration of onabotulinumtoxinA response through the 3 injection cycles of the study for Groups A, B, and C as measured by headache days per month.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Headache Days</measure>
    <time_frame>From day 29 (first day of injection cycle 1) to day 281 (84th day of injection cycle 3) plus or minus 12 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Comparison of headache days per month over each injection cycle between Groups A, B, and C.  Subjects will remain in their assigned groups based on assessment at 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Migraine Disability Assessment Scale (MIDAS)</measure>
    <time_frame>From day 29 (first day of injection cycle 1) to day 281 (84th day of injection cycle 3) plus or minus 12 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Comparison between Group A, B, and C for MIDAS scores measured at baseline and weeks 12, 24, and 36.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Social Readjustment Rating Scale (SRRS)</measure>
    <time_frame>From day 29 (first day of injection cycle 1) to day 281 (84th day of injection cycle 3) plus or minus 12 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Comparison between Group A, B, and C for SRRS scores measured at baseline and weeks 12, 24, and 36.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician Global Impression of Change (PGIC)</measure>
    <time_frame>From day 1 (first day of baseline) to day 281 (84th day of injection cycle 3) plus or minus 12 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Comparison between Group A, B, and C for PGIC scores measured at baseline and weeks 12, 24, and 36.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Depression Inventory II (BDI-II)</measure>
    <time_frame>From day 29 (first day of injection cycle 1) to day 281 (84th day of injection cycle 3) plus or minus 12 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Comparison between Group A, B, and C for BDI-II scores measured at baseline and weeks 12, 24, and 36.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>State-Trait Anxiety Inventory (STAI)</measure>
    <time_frame>From day 29 (first day of injection cycle 1) to day 281 (84th day of injection cycle 3) plus or minus 12 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Comparison between Group A, B, and C for STAI scores measured at baseline and weeks 12, 24, and 36.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Quality Questionnaire</measure>
    <time_frame>From day 29 (first day of injection cycle 1) to day 281 (84th day of injection cycle 3) plus or minus 12 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Comparison between Group A, B, and C for sleep quality scores measured at baseline and weeks 12, 24, and 36.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Medication Usage</measure>
    <time_frame>From day 1 (first day of baseline) to day 281 (84th day of injection cycle 3) plus or minus 12 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Comparison of acute medication usage between Groups A, B, and C.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Consistency of Response to onbotulinumtoxinA Over Three Injection Cycles</measure>
    <time_frame>From day 29 (first day of injection cycle 1) to day 281 (84th day of injection cycle 3) plus or minus 12 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Compare the consistency of duration of onabotulinumtoxinA response by the group assignment at 12 weeks to assessments at 24, and 36 weeks evaluations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuronal Regrowth</measure>
    <time_frame>From day 29 (first day of injection cycle 1) to day 197 (84th day of injection cycle 2) plus or minus 6 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Correlate neuronal regrowth in the skin biopsies with duration of benefit of onabotulinumtoxinA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of onabotulinumtoxinA Over 3 Injection Cycles</measure>
    <time_frame>From day 29 (first day of injection cycle 1) to day 281 (84th day of injection cycle 3) plus or minus 12 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Compare duration of benefit of onabotulinumtoxinA response through 3 injection cycles for Groups A, B, and C as measured by headache days per week.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Chronic Migraine</condition>
  <arm_group>
    <arm_group_label>onabotulinumtoxinA</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>onabotulinumtoxinA</intervention_name>
    <description>BOTOXÂ® (Formulation Number 9060X) contains 200 International Units (IU) of Clostridium botulinum Toxin Type A, reconstituted with 4 cc of normal saline providing 5 units per 0.1 cc. At visit 2, subjects will  receive their first treatment at Day 29 (+/-3 days).  All subjects will receive 155 U Botulinum Toxin Type A Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven (7) specific head/neck muscle areas.  Injections will be repeated at day 113 (+/- 3 days) and at day 197 (+/- 3 days).</description>
    <arm_group_label>onabotulinumtoxinA</arm_group_label>
    <other_name>Botox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male or female 18 years or older.

          -  able to read, understand, and sign the informed consent.

          -  a negative urine pregnancy test at visit 1, if female, and of childbearing potential.
             Note: If female of childbearing potential, subject must agree to maintain true
             abstinence or use  one of the listed methods of birth control for the duration of the
             study: hormonal contraceptive, intrauterine device (IUD), condoms, diaphragm, and/or
             have a male partner who has undergone a successful vasectomy. The use of barrier
             contraceptive (condom or diaphragm) should always be supplemented with the use of a
             spermicide.

        Note: To be considered not of childbearing potential, subject must be 6 weeks
        post-surgical bilateral oophorectomy, hysterectomy, bilateral tubal ligation,
        postmenopausal for at least one year.

          -  at least a one year history of migraine

          -  history of chronic migraine (with or without aura) according to the criteria of the
             International Classification of Headache Disorders (ICHD)-3 for at least 3 months
             prior to enrollment (Appendix I)

          -  able to differentiate migraine headache from any other headache they may experience
             (e.g., cluster headache)

          -  onset of migraine before age 50

          -  willing to provide responses to questionnaires and complete the online diary.

          -  if taking migraine preventive(s), be on a stable dose of the preventive medication
             for at least 30 days prior to screening

          -  concomitant medication dosages approved by the investigator

          -  email and internet access for completion of online diary

        Exclusion Criteria:

          -  previously used onabotulinumtoxinA as a migraine preventative or has used
             onabotulinumtoxinA for any other reason during the prior year

          -  female who is pregnant, planning to become pregnant during the study period, breast
             feeding, or is of childbearing potential and not practicing a reliable form of birth
             control

          -  headache disorders outside ICHD-3 defined chronic migraine that cannot be easily
             distinguished from CM (Appendix I)

          -  evidence of underlying pathology contributing to their headaches

          -  any medical condition that may increase their risk with exposure to BTX including
             diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis,
             or any other significant disease that might interfere with neuromuscular function

          -  profound atrophy or weakness of muscles in the target areas of injection

          -  skin conditions or infections at any of the injection sites

          -  allergy or sensitivities to any component of the test medication

          -  in the opinion of the investigator, has an active major psychiatric disorder
             including substance abuse and/or substance dependence within the last 12 months as
             determined by the investigator.

          -  Medication Overuse Headache as defined by ICHD-3 criteria for opioid or butalbital
             containing products (Appendix II)

          -  planning or requiring surgery during the study

          -  a history of poor compliance with medical treatment

          -  currently participating in an investigational drug study or has participated in an
             investigational drug study within the previous 30 days of the screening visit
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roger K Cady, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinvest/A Division of Banyan Group,Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeanne G Tarrasch, BSN, RN</last_name>
    <phone>417-841-3673</phone>
    <email>jtarrasch@clinvest.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Heather R Manley, MS, LPC</last_name>
    <phone>417-841-3664</phone>
    <email>hmanley@clinvest.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinvest/A Division of Banyan Group, Inc.</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alice Oh, LPN</last_name>
      <phone>417-841-3681</phone>
      <email>aoh@clinvest.com</email>
    </contact>
    <contact_backup>
      <last_name>Sami Louzader, BA, RN</last_name>
      <phone>417-841-3659</phone>
      <email>slouzader@clinvest.com</email>
    </contact_backup>
    <investigator>
      <last_name>Roger K Cady, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kent Dexter, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 2, 2014</lastchanged_date>
  <firstreceived_date>January 14, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Migraine</keyword>
  <keyword>onabotulinumtoxinA</keyword>
  <keyword>Headache</keyword>
  <keyword>Migraine</keyword>
  <keyword>Neuronal regrowth</keyword>
  <keyword>Botox</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
